Psych Flashcards
Monitoring of antipsychotics
- BMI (every visit > q3 months)
- FBG (q3 months > annual)
- Lipid panel (q3 months > q6 months)
- Prolactin (baseline)
- BP (q3 months > annual)
- EPSE (q3 months > annual)
- WBC/ANC (weekly x 18 months > monthly)
TCA drug interactions
- Tertiary amines (amitriptyline, imipramine): 2D6, 3A4 metabolism
- Secondary amines (nortriptyline, desipramine): 2D6 metabolism
Special SSRI administration
- Fluoxetine (in AM)
- Sertraline (with food)
Additional side effects of SNRIs
Diaphoresis
Raised BP (venlafaxine)
Reduced appetite, urinary hesitancy (duloxetine)
Benefit of mixed serotonergic agents
Mirtazapine (less GI, less sexual dysfunction)
Vortioxetine (lMess GI)
Management of dystonia and pseudo-parkinsonism
Anticholinergics i.e. Benzhexol
Management of akathisia
PRN Clonazepam
Propranolol 20 mg TDS
Management of tardive dyskinesia
Worsened with anticholinergics
PRN Clonazepam
Valbenazine
Management of hyperprolactinemia
Dopamine agonists (amantadine, bromocriptine)
Switch to aripiprazole, bexpiprazole
Differential QTc prolonging effect of antipsychotics
- Chlorpromazine
- Ziprasidone
- Haloperdol
- Quetiapine
- Risperidone
- Olanzapine
Management of neuroleptic malignant syndrome
IV Dantrolene
1A2 inhibitors
Fluvoxamine
Ciprofloxacin
2C19 inhibitors
Fluvoxamine
Omeprazole
Fluoxetine, voriconazole
2D6 inhibitors
Fluoxetine
Paroxetine
Bupropion
Adequate trial for antipsychotics
2-6 weeks at therapeutic range